Stock Events

Stock Events

Tempest Therapeutics 

$1.2550
132
+$0.00+0.4% Today

Statistics

Day High
1.2999
Day Low
1.2405
52W High
12.23
52W Low
1.22
Volume
249,876
Avg. Volume
200,443
Mkt Cap
5.57M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-4.03
-2.78
-1.53
-0.28
Expected EPS
-0.3
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-83.69MNet Income

Analyst Ratings

11.00Average Price Target
The highest estimate is 11.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TPST. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap110.27B
Bristol Myers Squibb is a leading biopharmaceutical company focusing on cancer therapies, directly competing with Tempest Therapeutics' oncology focus.
Merck
MRK
Mkt Cap281.24B
Merck & Co., Inc. is a global healthcare company that develops cancer drugs, competing in the same therapeutic areas as Tempest Therapeutics.
Pfizer
PFE
Mkt Cap143.68B
Pfizer Inc. has a broad portfolio of oncology drugs, making it a direct competitor in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap153.66B
Gilead Sciences, Inc. is known for its strong presence in the oncology sector, competing with Tempest Therapeutics in developing cancer therapies.
AMGEN
AMGN
Mkt Cap182.21B
Amgen Inc. focuses on human therapeutics, including oncology, which puts it in direct competition with Tempest Therapeutics.
Novartis
NVS
Mkt Cap280.64B
Novartis AG is a multinational pharmaceutical company with a significant focus on oncology, competing in the same market as Tempest Therapeutics.
Roche
RHHBY
Mkt Cap320.37B
Roche Holding AG is a major player in the oncology market, with a wide range of cancer treatments that compete with Tempest Therapeutics.
Astrazeneca
AZN
Mkt Cap271.29B
AstraZeneca PLC has a strong oncology portfolio, making it a key competitor in the cancer therapy market.
Johnson & Johnson
JNJ
Mkt Cap549.78B
Johnson & Johnson, through its pharmaceutical division Janssen, develops cancer drugs, competing with Tempest Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap63.95B
Regeneron Pharmaceuticals, Inc. is involved in developing treatments for cancer, among other diseases, competing in the oncology space with Tempest Therapeutics.

About

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Show more...
CEO
Mr. Justin Trojanowski CPA
Employees
24
Country
United States
ISIN
US87978U2078

Listings

MU
DE
3OS0.MU
F
DE
3OS0.F
STU
DE
3OS0.STU
XNAS
US
TPST

0 Comments

Share your thoughts

FAQ

What is Tempest Therapeutics stock price today?▼
The current price of TPST is $1.26 USD — it has increased by +0.4% in the past 24 hours. Watch Tempest Therapeutics stock price performance more closely on the chart.
What is Tempest Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tempest Therapeutics stocks are traded under the ticker TPST.
Is Tempest Therapeutics stock price growing?▼
TPST stock has risen by +0.4% compared to the previous week, the month change is a -32.53% fall, over the last year Tempest Therapeutics has showed a -63.36% decrease.
What is Tempest Therapeutics market cap?▼
Today Tempest Therapeutics has the market capitalization of 5.57M
When is the next Tempest Therapeutics earnings date?▼
Tempest Therapeutics is going to release the next earnings report on August 17, 2026.
What were Tempest Therapeutics earnings last quarter?▼
TPST earnings for the last quarter are -2.53 USD per share, whereas the estimation was -0.28 USD resulting in a -803.57% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tempest Therapeutics revenue for the last year?▼
Tempest Therapeutics revenue for the last year amounts to 0 USD.
What is Tempest Therapeutics net income for the last year?▼
TPST net income for the last year is -83.69M USD.
How many employees does Tempest Therapeutics have?▼
As of June 23, 2026, the company has 24 employees.
In which sector is Tempest Therapeutics located?▼
Tempest Therapeutics operates in the Health & Wellness sector.
When did Tempest Therapeutics complete a stock split?▼
The last stock split for Tempest Therapeutics was on January 30, 2026 with a ratio of 2:1.
Where is Tempest Therapeutics headquartered?▼
Tempest Therapeutics is headquartered in Brisbane, United States.